SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

Corvus Pharma Highlights Data On Refinement Of Adenosine Gene Signature, Ciforadenant In Renal Cell Cancer At ASCO

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel

Benzinga · 05/13/2020 21:57

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today announced that updated data reporting refinements of the Adenosine Gene Signature  as a predictive biomarker for patients treated with ciforadenant, the Company’s adenosine A2A receptor antagonist, will be presented in an electronic poster presentation at the American Society of Clinical Oncology’s (ASCO) upcoming ASCO20 Virtual Scientific Program, to be held May 29-31, 2020.

The data is based on results from  the Company’s Phase 1b/2 clinical trial of ciforadenant in patients with advanced refractory renal cell cancer (RCC) and demonstrates the potential role of CD68 positive myeloid cells, which are a downstream target of adenosine, as a biomarker to further enrich for responding patients. The electronic poster will be available for on-demand viewing starting at 8:00 am ET on Friday, May 29, 2020. The details are as follows:

Title: CD68+ tumor-associated myeloid cells as the target of adenosine-induced gene products and predictor of response to adenosine blockade with ciforadenant (cifo) in renal cell cancer (RCC).
Poster #: 94
Lead Author: Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center
Session: Genitourinary Cancer – Kidney and Bladder

The abstract related to the poster (#5025) is available now at https://meetinglibrary.asco.org/. The electronic poster presentation will include additional data not available in the abstract.